<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121080</url>
  </required_header>
  <id_info>
    <org_study_id>R2222-HV-1326</org_study_id>
    <nct_id>NCT02121080</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety,&#xD;
      tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in&#xD;
      cohorts of healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.</measure>
    <time_frame>from day 1 up to week 20 (EOS)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>from day 1 over time up to week 20</time_frame>
    <description>Serum concentration of REGN2222 over time up to week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of antibodies</measure>
    <time_frame>from day 1 over time up to week 20</time_frame>
    <description>The presence or absence of antibodies against REGN2222 over time up to week 20</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2222(SAR438584)</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A healthy man or woman aged 18 to 60 years&#xD;
&#xD;
          2. Body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive&#xD;
&#xD;
          3. Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          4. Provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum hemoglobin, creatinine, alkaline phosphatase, CPK, and/or hepatic enzymes&#xD;
             (aspartate aminotransferase [AST] and alanine aminotransferase [ALT], total bilirubin&#xD;
             [unless the investigator has evidence that increased bilirubin corresponds to a&#xD;
             Gilbert's type syndrome with elevated indirect bilirubin]) that is &gt;1.5 the upper&#xD;
             limit of normal (ULN), or any laboratory findings showing evidence of organ&#xD;
             dysfunction or any clinically significant abnormalities from the normal range, as&#xD;
             determined by the investigator at the screening visit&#xD;
&#xD;
          2. Use of any concomitant medications within 30 days or at least 5 half-lives, whichever&#xD;
             is longer, of the screening visit, including prescription medications (except&#xD;
             contraceptives), nutritional supplements, and over-the-counter medications (except&#xD;
             acetaminophen)&#xD;
&#xD;
          3. Hospitalization for any reason within 60 days of the screening visit&#xD;
&#xD;
          4. History of or positive human immunodeficiency virus (HIV) screen result at the&#xD;
             screening visit&#xD;
&#xD;
          5. History of or positive blood test result for hepatitis B surface antigen and/or&#xD;
             hepatitis C virus antibody at the screening visit&#xD;
&#xD;
          6. History of autoimmune disease&#xD;
&#xD;
          7. History of respiratory disease (e.g, asthma, chronic obstructive pulmonary disease)&#xD;
&#xD;
          8. History of drug or alcohol abuse within 1 year prior to the screening visit&#xD;
&#xD;
          9. Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days, or within at least 5 half-lives, of the investigational&#xD;
             drug (whichever is longer) prior to the screening visit&#xD;
&#xD;
         10. Pregnant or breastfeeding woman&#xD;
&#xD;
         11. Sexually active men* or women of childbearing potential** who are unwilling to&#xD;
             practice adequate contraception during the study, and up to 3 months after the last&#xD;
             dose of the study drug (adequate contraceptive measures include stable use of oral&#xD;
             contraceptives or other prescription pharmaceutical contraceptives for 2 or more&#xD;
             menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation;&#xD;
             vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus&#xD;
             contraceptive sponge, foam, or jelly)&#xD;
&#xD;
               -  Contraception is not required for men with documented vasectomy. **Postmenopausal&#xD;
                  women must be amenorrheic for at least 12 months in order not to be considered of&#xD;
                  childbearing potential. Contraception is not required for women with documented&#xD;
                  hysterectomy or tubal ligation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

